Development and evaluation of a self-emulsifying drug delivery system of amphotericin B

Asian Journal of Pharmaceutics

Volumn 6, Issue 2, 2012, Pages 124-129

  Bhattacharyya, Arundhati ^a   Bajpai, Meenakshi ^b  

^a RAJ KUMAR GOEL INSTITUTE OF TECHNOLOGY   (India)

^b UTTARAKHAND TECHNICAL UNIVERSITY   (India)

Author keywords

Amphotericin B; dissolution; intestinal permeability; self emulsifying drug delivery system

Indexed keywords

AMPHOTERICIN B; MACROGOL; PROPYLENE GLYCOL; SURFACTANT;

ANIMAL TISSUE; ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG SCREENING; DRUG SOLUBILITY; EMULSION; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; PRECIPITATION; SUSPENSION;

EID: 84870268613     PISSN: 09738398     EISSN: 1998409X     Source Type: Journal    
DOI: 10.4103/0973-8398.102936     Document Type: Article

References (26)

1. Pouton CW. Lipid formulations for oral administration of drugs: Nonemulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci 2000;11:S93-8.
2. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: Physical and biopharmaceutical aspects. Pharm Res 1995;12:1561-72.
3. Kim HJ, Yoon KA, Hahn M, Park ES, Chi SC. Preparation and in vitro evaluation of self-microemulsifying drug delivery systems containing idebenone. Drug Dev Ind Pharm 2000;26:523-9.
4. Kang BK, Lee JS, Chon SK, Jeong SY, Yuk SH, Khang G, et al. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm 2004;274:65-73.
5. Shah NH, Carvajal MT, Patel CI, Infeld MH, Malick AW. Self-emulsifying drug delivery systems (SEDDS) with polyglycolysed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm 1994;106:15-23.
6. Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ, Pouton CW. Self-emulsifying drug delivery systems: Formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm Res 1992;9:87-93.
7. Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: Formulation development and bioavailability assessment. Int J Pharm 2001;212:233-46.
8. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004;58:173-82.
9. Meyer RD. Current role of therapy with amphotericin B. Clin Infect Dis 1992;14(Suppl 1):S154-60.
10. Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P. Comparison of three treatment regimens with liposomal amphotericin b (Ambisome) for visceral leishmaniasis in India: A randomized dose finding study. Trans R Soc Trop Med Hyg 1996;90:319-22.
11. Rajagopalan N, Chen SC, Chow W. A study of the inclusion complex of amphotericin B with γ:cyclodextrin. Int J Pharm 1986;29:161-8.
12. Bajpai M, Verma KC. Studies on amphotericin B solid dispersions prepared using blend of carriers. The Eastern Pharmacist 1981;24:187-8.
13. Dangi JS, Vyas SP, Dixit VK. Effect of various lipid-bile salt mixed micelles on the intestinal absorption of amphotericin B in rat. Drug Dev Ind Pharm 1998;24:631-5.
14. Kayser O, Olbrich C, Yardley V, Kiderlen AF, Croft SL. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 2003;254:73-5.
15. Santangelo R, Paderu P, Delmas G, Chen ZW, Mannino R, Zarif L, et al. Efficacy of oral cochleate:amphptericin B in a mouse model of systemic candidiasis. Antimicrob Agent Chemother 2000;44:2356-60.
16. Zarif L, Graybill JR, Perlin D, Najvar L, Bocanegra R, Mannino RJ. Antifungal activity of Amphotericin B cochleates against candida albicans infection in a mouse model. Antimicrob Agent Chemother 2000;44:1463-9.
17. Risovic V, Sachs-Barrable K, Boyd M, Wasan KM. Potential mechanisms by which Peceol increases the gastrointestinal absorption of amphotericin B. Drug Dev Ind Pharm 2004;30:767-74.
18. Wasan EK, Bartlett K, Gershkovich P, Sivak O, Banno B, Wong Z, et al. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Int J Pharm 2009;372:76-84.
19. Gershkovich P, Wasan EK, Lin M, Sivak O, Leon CG, Clement JG, et al. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J Antimicrob Chemother 2009;64:101-8.
20. Risovic V, Boyd M, Choo E, Wasan KM. Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats. Antimicrob Agent Chemother 2003;47:3339-42.
21. Würthwein G, Groll AH, Hempel G, Adler:Shohet FC, Lieberman JM, Walsh TJ, et al. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agent Chemother 2005; 49:5092-8.
22. Ruan LP, Chen S, Yu BY, Zhu DN, Cordell GA, Qiu SX. Prediction of human absorption of natural compounds by the non-everted rat intestinal sac model. Eur J Med Chem 2006;41:605-10.
23. Yamsani SK, Gannu R, Devandla A, Yamsani VV, Palem CR, Ravula SK, et al. Effect of silymarin and pomegranate pretreatment on intestinal transport of buspirone across rat intestine. Acta Pharmaceutica Sciencia 2009;51:289-96.
24. Adams ML, Kwon GS. Relative aggregation state and hemolytic activity of amphotericin B encapsulated by poly(ethylene oxide):block:poly (N:hexyI:I:aspartamide)acyl conjugate micelles: Effects of acyl chain length. Biochim Biophys Acta 1980;599:280-93.
25. Johnson BM, Charman WN, Porter CJ. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d: alphatocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte:based metabolism in excised rat intestine AAPS PharmSci 2002;4-E40.
26. Zhang H, Yao M, Morrison RA, Chong S. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res 2003;26:768-72.